SGD Pharma, a French leader in primary packaging for the pharmaceutical industry, has acquired Alphial S.r.l., an Italian manufacturer specializing in pharmaceutical primary packaging, for an undisclosed amount. This corporate acquisition is set to significantly strengthen both companies' positions in the vital pharmaceutical supply chain.
Alphial S.r.l. emerged from the merger of SM Pack, Crestani, Nuova Vitrofin, Luxenia, and Sicatef, establishing itself as one of Europe's largest manufacturers of pharmaceutical primary packaging. Operating five plants across Italy, Alphial focuses on transforming I° class hydrolytic tubular glass into high-quality ampoules and vials. The company offers a range of products including tubing glass ampoules, standard and pre-washed vials, and ready-to-use (RTU) sterile and pyrogen-free vials, serving the pharmaceutical, chemical, and cosmetic industries, particularly for injectable drugs and biotechnological solutions.
This acquisition represents a strategic move for SGD Pharma to enhance its product portfolio and expand its manufacturing footprint. The integration of Alphial's specialized capabilities, such as its innovative RTU vial solutions and extensive glass ampoule and vial production, complements SGD Pharma's existing leadership in the primary packaging sector. Synergies are expected through combined expertise, increased production capacity, and a broader offering of advanced glass packaging solutions for critical pharmaceutical applications.
The unified entity is poised to solidify its role as a key player in the European and global pharmaceutical primary packaging market. By combining Alphial’s commitment to innovation and quality with SGD Pharma's market leadership, the acquisition aims to deliver enhanced solutions and services, supporting patient health worldwide through reliable and high-standard packaging. This move underscores a focus on strengthening capabilities to meet the evolving demands of the pharmaceutical industry.